Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidatesIambic to receive up to $25...
Chicago-based physician to contribute through Anosh Inc Foundation and host local fundraiser in support of federal agents Image by Dr....
Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as...
Appointment highlights DIMERx’s next phase of growth as it advances non-addictive pain therapeutics with support from the NIH HEAL InitiativeSAN...
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
PORTLAND, Maine, July 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
-- Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts,...
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve...
CARSON CITY, Nev., July 09, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company...
BRIDGEWATER, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical...
NORCROSS, Ga., July 09, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with...
Presentation also given at the 20th World Congress of the International Pancreas & Islet Transplant Association (IPITA)WALTHAM, Mass., July 09,...
-In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301...
Proceeds used to retire $68 million of existing debt with the remainder designated for future growth initiatives Additional facility of...
Pharma Vet brings 20+ years of Legal, Compliance, and Commercialization Expertise as Company prepares ADHD Drug FilingKANSAS CITY, Kan., July...
Proceeds to support key development milestones, including CMC advancement, initiation of a Phase I clinical trial in the first half...
- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term...
ART26.12, a Novel FABP5 Inhibitor, Demonstrates Sustained Analgesic Effects Without ToleranceSOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Artelo...
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides clear regulatory pathway to approval in a continuous Phase 1 /...
Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1...